A study found that patients with a mutation in ARID1A and expression of immune cytokine CXCL13 had better overall survival on immune checkpoint inhibitors.
With studies showing BRCA-mutated patients have a greater magnitude of benefit, oncologists grapple with complex treatment decisions in BRCA mutation-free cases.
Two studies presented at ASCO's virtual annual meeting demonstrated the clinical utility of germline findings in guiding treatment decisions in cancer.
The company, which recently wrapped enrollment for a Phase II trial in China, is continuing to actively enroll patients in the US trial for the drug despite the COVID-19 pandemic.
The analysis presented at the AACR Virtual Annual Meeting confirmed the effectiveness of the TRK inhibitor to treat cancer patients with NTRK gene fusions.
Additional analyses found the talazoparib arm reported a better quality of life and a limited effect of broader tumor genomic markers on clinical benefit or progression-free survival.
A Phase II study suggests immune-related expression signatures and other immune markers may help find metastatic prostate cancer cases with better checkpoint blockade response.
Researchers showed that detectable ctDNA following chemoradiation may identify lung cancer patients who will likely have disease recurrence and should receive consolidation immunotherapy.
